<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types
Background Image

Rodent Immuno-Safety Models

De-risk drug development with early toxicity screening of immunotherapeutic compounds

In Vivo Models of irAE for Safety and Toxicity Screening of Immunotherapies

Study unique immune-related adverse events (irAEs) associated with immunotherapies, using HuGEMM™ and HuCELL™ human target knock-in models. The platforms feature humanized drug targets within a fully functional murine immune system, providing an ideal method for assessing the complex nature of on-target and off-target toxicities of human-specific immunotherapies.

Efficacy and toxicity of human-specific therapies can be assessed in the same animal, enabling determination of the optimal therapeutic window in the same species and providing quick, cost-effective, and robust data to guide future drug development work.

Benefits of the HuGEMM Platform for Safety and Toxicity Screening

  • Efficiently study the safety of a range of targets for human immunotherapies
  • Enable determination of therapeutic index in the same species by assessing both efficacy and toxicity
  • Improve cost effectiveness with onsite pathology/histopathology services, including IHC, ICC, and IF
  • Rapid study initiation for fast turnaround of robust results - study duration optimized to fit client and project needs

Focused Toxicology Analysis of Immunotherapeutic Agents

  • Immune checkpoint inhibitors
  • Immune checkpoint stimulators
  • Bi-specific antibodies
  • Antibody-drug conjugates (ADCs)

Available Models


Currently Available HuGEMM Models for Safety and Toxicity Evaluation

HuGEMM models are immunocompetent chimeric mouse models, engineered to express humanized drug targets (instead of their murine counterparts) such as genes encoding for immune checkpoint proteins.

Single Knock-in Double Knock-in Triple Knock-in
B7H3 TIGIT/PVR CD47/Sirpα/PD-1
BTLA PD-L1/TIM-3 CD47/Sirpα/PD-L1
CD137 PD-L1/LAG3 PD-1/PD-L1/IDO-1
CD28 PD-L1/CD47 PD-1/PD-L1/OX40
CD39 PD-L1/CD27 PD-1/PD-L1/TIM-3
CD40 PD-1/Tim3  
CD73 PD-1/Sirpα  
CTLA4 PD-1/PD-L1  
GITR PD-1/OX40  
IL-1b PD-1/LAG3  
OX40 PD-1/CTLA4  
OX40L PD-1/CD47  
PD-1 PD-1/CD40  
PD-L1 PD-1/CD28  
SIGLEC15 PD-1/CD27  
Sirpα PD-1/CD137  
TIGIT OX40/CD137  
TIM-3 NKG2A/CD94  

Explore Our Collection

Sample Data


Safety and Toxicity Readouts Available

  • Cytokine analysis
  • Liver function tests (ALT, AST)
  • Histopathological evaluation of organ toxicity
  • Immune cell infiltration in target organs by IHC, Flow cytometry
  • Complete blood count (CBC)
  • Clinical observations to identify potential adverse effects related to cytokine storm/CRS

Fig 1. The tumor growth inhibition of urelumab and chimeric urelumab on murine colon tumor CT26.WT in CD137 HuGEMM model. Tumor growth inhibition (TGI) was calculated as: TGI% = (1-Ti/Vi)*100; Ti as the mean tumor volume of the treatment group on the measurement day; Vi as the mean tumor volume of control group at the measurement day.

Fig 2. Measurement of liver toxicity based on ALT (alanine aminotransferase) and AST (aspartate aminotransferase) levels in CD137 HuGEMM animals. Fasting serum level of ALT (alanine aminotransferase) and AST (aspartate aminotransferase) were measured 2 and 7 days after final dose. One way ANOVA *, **, and *** refer to p<0.05, p<0.01, and p<0.001, respectively.

Fig 3. Histological assessment of liver inflammation following urelumab and chimeric urelumab treatment in CD137 HuGEMM in vivo model. H&E staining of liver tissue. Liver inflammation was evaluated on a scale of 0-3: 0 = none; 1 = mild; 2 = moderate; 3 = severe.

Fig 4. Infiltration of CD45+ immune cells in the liver following urelumab and chimeric urelumab treatment in CD137 HuGEMM in vivo model, as indicated by IHC staining - CD45+ cell density were measured by HALO v3.0.311.363.


Discuss Your Rodent Immuno-Safety Model Project

Tell us about your needs